Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial
- PMID: 17659757
Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial
Abstract
Objective: To study prospectively the effect of treatment with cyclophosphamide pulses (CYC) or azathioprine with methylprednisolone (AZA), both for 24-month periods, on health-related quality of life (HRQOL) in patients with proliferative lupus nephritis (LN) in a randomized controlled trial. We expected better HRQOL during AZA treatment.
Methods: HRQOL and disease activity were measured at start and after 12 and 24 months. Generic questionnaires [patient's visual analog scale (VAS), Medical Outcomes Study Short Form-36 Health Survey (SF-36), Profile of Mood States] and a disease-specific measure [Systemic Lupus Erythematosus (SLE) Symptom Checklist] were used. Treatment burden was assessed at 24 months. Disease activity was measured with the SLE Disease Activity Index (SLEDAI) and physician's VAS.
Results: Complete questionnaire data were available from 47 of the 87 patients included in the trial. These patients were representative of the whole group, except that completers were more often Caucasian. HRQOL scores improved significantly during treatment, particularly during the first year, on both generic and disease-specific outcomes. No statistically significant differences were found in HRQOL between the CYC and AZA groups, except for the SF-36 mental component summary scale, which showed more favorable scores in the AZA group. The mean reported treatment burden at 24 months was significantly higher in the CYC group. HRQOL scores did not correlate with the SLEDAI and physician's VAS. The disease activity measures correlated positively with each other.
Conclusion: Treatment of patients with proliferative LN with immunosuppressive drugs and corticosteroids improves HRQOL, particularly in the first year. Due to the small groups studied, the absence of differences between AZA and CYC for most HRQOL scales should be interpreted cautiously: our data suggest that there may be no significant differences. Differences were a higher perceived treatment burden and worse mental HRQOL in the CYC group.
Similar articles
-
Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.Arthritis Rheum. 2007 Mar;56(3):924-37. doi: 10.1002/art.22449. Arthritis Rheum. 2007. PMID: 17328070 Clinical Trial.
-
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.Arthritis Rheum. 2007 May;56(5):1676-84. doi: 10.1002/art.22580. Arthritis Rheum. 2007. PMID: 17469162 Clinical Trial.
-
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461. Arthritis Rheum. 2002. PMID: 12209517 Clinical Trial.
-
Outcome assessment in lumbar spine surgery.Acta Orthop Suppl. 2005 Jun;76(318):5-47. Acta Orthop Suppl. 2005. PMID: 16175972 Review.
-
Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects.Best Pract Res Clin Rheumatol. 2009 Aug;23(4):457-67. doi: 10.1016/j.berh.2009.01.007. Best Pract Res Clin Rheumatol. 2009. PMID: 19591777 Review.
Cited by
-
A Focus Group Study of Self-Management in Patients With Glomerular Disease.Kidney Int Rep. 2021 Oct 30;7(1):56-67. doi: 10.1016/j.ekir.2021.10.011. eCollection 2022 Jan. Kidney Int Rep. 2021. PMID: 35005314 Free PMC article.
-
A systematic literature review of the assessment of treatment burden experienced by patients and their caregivers.BMC Geriatr. 2019 Oct 11;19(1):262. doi: 10.1186/s12877-019-1222-z. BMC Geriatr. 2019. PMID: 31604424 Free PMC article.
-
Immunosuppressive treatment for proliferative lupus nephritis.Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4. Cochrane Database Syst Rev. 2018. PMID: 29957821 Free PMC article.
-
Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies.Rheumatol Ther. 2021 Sep;8(3):1287-1301. doi: 10.1007/s40744-021-00338-4. Epub 2021 Jul 9. Rheumatol Ther. 2021. PMID: 34244970 Free PMC article.
-
Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis.Int J Nephrol. 2015;2015:917567. doi: 10.1155/2015/917567. Epub 2015 Oct 27. Int J Nephrol. 2015. PMID: 26600951 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources